Rhythm Pharmaceuticals, Inc. (RYTM)

35,68 -1,00 (-2,73%) Alla chiusura: 04:00PM EDT

Rhythm Pharmaceuticals, Inc.

222 Berkeley Street
12th Floor
Boston, MA 02116
United States
857 264 4280
https://rhythmtx.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 226

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. David P. Meeker M.D.	Chairman, President & CEO	1,35M	N/D	1954
Mr. Hunter C. Smith M.B.A.	CFO & Treasurer	757,32k	1,88M	1969
Mr. Joseph Shulman	Chief Technical Officer	677,27k	968,13k	1976
Mr. Yann Mazabraud	Executive VP & Head of International	936,91k	N/D	1973
Ms. Jennifer Lee	Executive VP & Head of North America	727,14k	779,08k	1976
Mr. Christopher German	Corporate Controller, Principal Accounting Officer & Executive Director	N/D	N/D	1971
Mr. David Connolly	Head of Investor Relations & Corporate Communications	N/D	N/D	N/D
Mr. Jim Flaherty	Senior VP & General Counsel	N/D	N/D	N/D
Ms. Sarah Ryan	Vice President of Sales & Marketing	N/D	N/D	N/D
Ms. Pamela J. Cramer	Chief Human Resources Officer	N/D	N/D	1975

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Rhythm Pharmaceuticals, Inc. al 1 giugno 2024 è 7. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.